September 11th 2024
Your daily dose of the clinical news you may have missed.
September 10th 2024
September 6th 2024
Across two clinical trials in the QWINT program, once-wekly efsitora showed comparable A1C reduction to frequently used daily insulins.
September 3rd 2024
August 29th 2024
Lanifibranor Plus Empagliflozin Effective in T2D, MASH: Proof-of-Concept Ph2 Findings
LEGEND phase 2 interim analysis findings include significant decreases in HbA1c in poorly controlled T2D and positive effects on several markers of liver injury.
Chronic Kidney Disease in Primary Care: Essential Basics Review
Primary care plays an essential role in identifying CKD, monitoring and slowing disease progression, and providing timely referral, when indicated, to nephrology.
Early Detection of CKD Progression in Primary Care: Daily Dose
Semaglutide Lowers CKD-Related Events in Persons with T2D, CKD: Daily Dose
Real-World Studies Show Significant HbA1c Reductions with GLP-1 RA and Freestyle Libre CGM Used Together
One study showed a significant 1.5% decrease in HbA1c 6 months after participants taking a GLP-1 RA started using the Freestyle Libre system.
FDA Clears First-Ever OTC Glucose Sensor: Dexcom Stelo Glucose Biosensor System
The Dexcom system is for adults over the age of 18 years who do not use insulin, such as individuals with T2D who use oral medications, a US population of 25 million.
Semaglutide Reduces CKD-Related Events by 24% in Population with T2D and CKD: FLOW Findings Announced
Semaglutide 1.0 mg was superior to placebo across the FLOW trial's 5-part primary endpoint with both CKD and CVD components contributing to risk reduction, said Novo Nordisk.
Rapid Progression of CKD Can Be Detected Early Using Simple Markers in Primary Care
The 3-year risk of rapid progression from CKD stage G3 was 15% in a large Danish population. Study authors identified accessible key risk factors to aid early detection.
Lowering Out-of-Pocket Rx Costs May Improve Diabetes Outcomes: Daily Dose
Tighter Glycemic Control in T2D Reduces Risk for All-Cause Dementia: Daily Dose
SGLT2 Inhibitors Outperformed Other Oral Antidiabetic Drugs for Persons with T2D, NAFLD: Daily Dose
Tighter Glycemic Control in Type 2 Diabetes May Reduce Risk for All-Cause Dementia: New Findings
Comprehensive management of T2D in primary care settings reduced risk of all-cause dementia by 28%, with lower HbA1c linked to lower, but still elevated risk.
Preventive Health Screenings Continue to Lag Post-Pandemic: Daily Dose
Reducing Out-of-Pocket Rx Costs May Help Improve Diabetes Outcomes, Particularly for those with Lower Incomes
Acute, preventable diabetes complications days fell by 8.4% among participants enrolled in a preventive drug list benefit and by even more among low-income subscribers.
SGLT2 Inhibitors Outperformed Other Oral Antidiabetic Drugs for Patients with T2D and NAFLD, According to New Research
Findings suggest that SGLT2 inhibitors may be the preferred choice for patients with both T2D and NAFLD, reported researchers.
Screenings for Cancer, Other Preventive Visits Continue to Lag Post-Pandemic
Preventive health screenings have yet to rebound to pre-COVID-19 levels and Asian adults appear to have fallen behind more than other racial/ethnic groups, a new study finds.
HbA1c Greater than 6.0% Raises T2D Risk in Children with Obesity: Daily Dose
Baseline HbA1c Greater than 6.0% Linked to "Exponential" Increase in T2D Risk for Adolescents with Obesity
Adolescents with overweight or obesity and baseline HbA1c 6.3%-6.4% were at 72-fold greater risk for T2D than those with HbA1c of 5.5%, a new cohort study finds.
Diabetes Remission of Any Duration May Reduce Risk of Renal and Cardiovascular Disease:
Remission of T2D, regardless of duration of remission, was associated with reduced risk of diabetes-related CKD and CVD in a post hoc analysis of Look AHEAD.
Newly FDA-Authorized Diabetes Digital Therapeutic Can be Cost-Effective, According to Modeling Study
The digital prescription therapeutic when used along with prescription diabetes therapies, can help reduce the costs of managing the disease and enhance standard of care.
Where is All the Wegovy Going? Highest and Lowest Prescribing States
The GLP-1 RAs Wegovy, Ozempic, Mounjaro, and Zepbound have taken up more real estate on the US map in some areas than others. Click to find out more.
Daily Dose: Semaglutide Not Linked to Suicide Ideation
FDA Review Suggest No Link Between GLP-1RAs and Suicidal Thoughts but Surveillance Will Continue
While the FDA's preliminary evaluation has not surfaced evidence of a link, the agency says it "cannot definitively rule out that a small risk may exist," and so will continue research.
Semaglutide Linked to Lower Risk of Suicidal Ideation in Patients with Obesity, Type 2 Diabetes
Semaglutide was associated with a lower risk of first-time and recurrent suicidal ideations in patients with obesity or overweight or T2D, according to new study.
Eli Lilly Open Letter Warns Against Use of Tirzepatide for "Cosmetic Weight Loss"
In an open letter to the public, Lilly decries use of tirzepatide products Mounjaro and Zepbound for nonmedical purposes and warns of counterfeit formulations.
Daily Dose: Cardiovascular Risk Factors Rising Among Middle-Aged Americans
CV Risk Factors Increasing Among Middle-Aged US Adults, Socioeconomic Inequities Persist: New Findings
Cardiovascular mortality has been increasing among middle-aged US adult since 2011; a new study looked at changes in CV risk factors by income level over the past 20 years.
"CKM Syndrome" Defines a Very Wide Target and Medicine is Ready, Says Chiadi Ndumele, MD, PhD, MHS
Ndumele chairs the American Heart Association committee that characterized the syndrome and wrote the statement of evidence for its assessment and management.
Tirzepatide Approved by FDA for Chronic Weight Management in Adults
The second GLP-1 mimetic-based drug approved for chronic weight management, tirzepatide may outperform semaglutide, the first.
It's High Time to Retire NAFLD: Multinational Liver Societies Explain
NAFLD, a term coined in the mid-nineteenth century but never an accurate name for the diseases it now stands for, was ready to go, agreed international experts.